Cargando…

The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma

OBJECTIVES: To evaluate the role of adjuvant radiation therapy in patients with locoregionally recurrent (rpT4/N1b) papillary thyroid carcinoma (PTC). METHODS: The medical records of patients with rpT4/N1b PTC who were treated between January 2001 and December 2016 were reviewed. A total of 57 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Hyun, Lee, Nam Kwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Saudi Medical Journal 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195542/
https://www.ncbi.nlm.nih.gov/pubmed/34344806
http://dx.doi.org/10.15537/smj.2021.42.8.20210127
_version_ 1784726987126865920
author Hwang, Hyun
Lee, Nam Kwon
author_facet Hwang, Hyun
Lee, Nam Kwon
author_sort Hwang, Hyun
collection PubMed
description OBJECTIVES: To evaluate the role of adjuvant radiation therapy in patients with locoregionally recurrent (rpT4/N1b) papillary thyroid carcinoma (PTC). METHODS: The medical records of patients with rpT4/N1b PTC who were treated between January 2001 and December 2016 were reviewed. A total of 57 patients were analyzed, of which 24 patients were treated with adjuvant radiation therapy, and 33 patients did not receive adjuvant radiation therapy. Survival outcomes were compared between the 2 treatment groups. The primary endpoint was locoregional recurrence-free survival rate. RESULTS: The median follow-up period for all patients was 10.3 years (range, 2.8-19.2 years). The 15-year locoregional recurrence-free survival rate was 80.5% for those who received adjuvant radiation therapy and 28.1% for those who did not (p<0.001). The 15-year distant metastasis-free survival rate was 48.8% for those who received adjuvant radiation therapy and 33.4% for those who did not (p=0.906). The 15-year overall survival rate was 69.7% for those who received adjuvant radiation therapy and 53.1% for those who did not (p=0.921). CONCLUSIONS: Adjuvant radiation therapy ensured favorable locoregional recurrence-free survival in patients with rT4/N1b PTC and might contribute to improving patients’ quality of life by reducing the need for additional salvage surgery and the economic burden of other salvage treatments, such as surgery or radioactive iodine therapy.
format Online
Article
Text
id pubmed-9195542
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Saudi Medical Journal
record_format MEDLINE/PubMed
spelling pubmed-91955422022-06-21 The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma Hwang, Hyun Lee, Nam Kwon Saudi Med J Original Article OBJECTIVES: To evaluate the role of adjuvant radiation therapy in patients with locoregionally recurrent (rpT4/N1b) papillary thyroid carcinoma (PTC). METHODS: The medical records of patients with rpT4/N1b PTC who were treated between January 2001 and December 2016 were reviewed. A total of 57 patients were analyzed, of which 24 patients were treated with adjuvant radiation therapy, and 33 patients did not receive adjuvant radiation therapy. Survival outcomes were compared between the 2 treatment groups. The primary endpoint was locoregional recurrence-free survival rate. RESULTS: The median follow-up period for all patients was 10.3 years (range, 2.8-19.2 years). The 15-year locoregional recurrence-free survival rate was 80.5% for those who received adjuvant radiation therapy and 28.1% for those who did not (p<0.001). The 15-year distant metastasis-free survival rate was 48.8% for those who received adjuvant radiation therapy and 33.4% for those who did not (p=0.906). The 15-year overall survival rate was 69.7% for those who received adjuvant radiation therapy and 53.1% for those who did not (p=0.921). CONCLUSIONS: Adjuvant radiation therapy ensured favorable locoregional recurrence-free survival in patients with rT4/N1b PTC and might contribute to improving patients’ quality of life by reducing the need for additional salvage surgery and the economic burden of other salvage treatments, such as surgery or radioactive iodine therapy. Saudi Medical Journal 2021-08 /pmc/articles/PMC9195542/ /pubmed/34344806 http://dx.doi.org/10.15537/smj.2021.42.8.20210127 Text en Copyright: © Saudi Medical Journal https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work.
spellingShingle Original Article
Hwang, Hyun
Lee, Nam Kwon
The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma
title The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma
title_full The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma
title_fullStr The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma
title_full_unstemmed The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma
title_short The role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma
title_sort role of adjuvant radiation therapy for locoregionally recurrent papillary thyroid carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9195542/
https://www.ncbi.nlm.nih.gov/pubmed/34344806
http://dx.doi.org/10.15537/smj.2021.42.8.20210127
work_keys_str_mv AT hwanghyun theroleofadjuvantradiationtherapyforlocoregionallyrecurrentpapillarythyroidcarcinoma
AT leenamkwon theroleofadjuvantradiationtherapyforlocoregionallyrecurrentpapillarythyroidcarcinoma
AT hwanghyun roleofadjuvantradiationtherapyforlocoregionallyrecurrentpapillarythyroidcarcinoma
AT leenamkwon roleofadjuvantradiationtherapyforlocoregionallyrecurrentpapillarythyroidcarcinoma